EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of “Buy” from Analysts
Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) have earned an average rating of “Buy” from the seven research firms that are currently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have covered the stock in the […]
More Stories
Western Alliance Bancorporation (NYSE:WAL) Price Target Increased to $92.00 by Analysts at Wells Fargo & Company
Western Alliance Bancorporation (NYSE:WAL – Free Report) had its price objective upped by Wells Fargo & Company from $85.00 to...
Western Alliance Bancorporation (NYSE:WAL) Price Target Increased to $92.00 by Analysts at Wells Fargo & Company
Western Alliance Bancorporation (NYSE:WAL – Free Report) had its price objective upped by Wells Fargo & Company from $85.00 to...
Visa (NYSE:V) PT Raised to $310.00
Visa (NYSE:V – Get Free Report) had its price objective boosted by research analysts at BMO Capital Markets from $300.00...
Visa (NYSE:V) PT Raised to $310.00
Visa (NYSE:V – Get Free Report) had its price objective boosted by research analysts at BMO Capital Markets from $300.00...
Barclays Trims Valero Energy (NYSE:VLO) Target Price to $146.00
Valero Energy (NYSE:VLO – Free Report) had its price target trimmed by Barclays from $165.00 to $146.00 in a research...
Barclays Trims Valero Energy (NYSE:VLO) Target Price to $146.00
Valero Energy (NYSE:VLO – Free Report) had its price target trimmed by Barclays from $165.00 to $146.00 in a research...